Siglec-1 and -2 as potential biomarkers in autoimmune disease

Amanda J Eakin; Michael J Bustard; Cathy M McGeough; Tahanver Ahmed; Anthony J Bjourson; David S Gibson

doi:10.1002/prca.201500069

Siglec-1 and -2 as potential biomarkers in autoimmune disease

Proteomics Clin Appl. 2016 Jun;10(6):635-44. doi: 10.1002/prca.201500069.

Authors

Amanda J Eakin¹, Michael J Bustard¹, Cathy M McGeough¹, Tahanver Ahmed¹, Anthony J Bjourson¹, David S Gibson¹

Affiliation

¹ Northern Ireland Centre for Stratified Medicine, Altnagelvin Hospital Campus, Ulster University, Londonderry, Northern Ireland, UK.

PMID: 26752092
DOI: 10.1002/prca.201500069

Abstract

Autoimmune diseases (ADs) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarize these findings with particular focus on sialic acid-binding immunoglobulin-like lectin (Siglec)-1 and Siglec-2 involvement in AD. Fluctuations in these glycosylation-dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.

Keywords: Autoimmune disease; Protein glycosylation; Sialic acid; Siglec receptor.

Publication types

Review

MeSH terms

Animals
Anti-Inflammatory Agents / therapeutic use
Autoimmune Diseases / drug therapy
Autoimmune Diseases / genetics
Autoimmune Diseases / immunology*
Autoimmune Diseases / pathology
Autoimmunity / drug effects
B-Lymphocytes / drug effects
B-Lymphocytes / immunology
B-Lymphocytes / pathology
Biomarkers / metabolism
Gene Expression Regulation
Glycosylation
Humans
Immunosuppressive Agents / therapeutic use
Macrophages / drug effects
Macrophages / immunology
Macrophages / pathology
Receptors, Leptin / genetics
Receptors, Leptin / immunology*
Sialic Acid Binding Ig-like Lectin 1 / genetics
Sialic Acid Binding Ig-like Lectin 1 / immunology*
Sialic Acid Binding Ig-like Lectin 2 / genetics
Sialic Acid Binding Ig-like Lectin 2 / immunology*
Signal Transduction
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology*
T-Lymphocyte Subsets / pathology

Substances

Anti-Inflammatory Agents
Biomarkers
CD22 protein, human
Immunosuppressive Agents
Receptors, Leptin
SIGLEC1 protein, human
Sialic Acid Binding Ig-like Lectin 1
Sialic Acid Binding Ig-like Lectin 2